Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 601–700 of 1,004
Andrade, M. D. O., Gutierres, I. G., Tavares, M. C., de Sousa, I. M., Balint, F. C., Comini, A. C. M., Gouveia, M. C., Bines, J., Madasi, F., Ferreira, R. D. P., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104473 · Cited by 32
“%) in the pathologic complete response (pCR) rate with the addition of pem-brolizumab to neoadjuvant therapy [3].”
Brandão, M., Morais, S., Lopes-Conceição, L., Fontes, F., Araújo, N., Dias, T., Pereira, D., Borges, M., Pereira, S., & Lunet, N. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000984 · Cited by 31
Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
Boissière‐Michot, F., Chabab, G., Mollévi, C., Guiu, S., Lopez‐Crapez, E., Ramos, J., Bonnefoy, N., Lafont, V., & Jacot, W. (2021) · Cancers · doi:10.3390/cancers13040765 · Cited by 28
Graeser, M., Feuerhake, F., Gluz, O., Volk, V., Hauptmann, M., Jóźwiak, K., Christgen, M., Küemmel, S., Grischke, E., Forstbauer, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002198 · Cited by 29
Sarradin, V., Lusque, A., Filleron, T., Dalenc, F., & Franchet, C. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01437-4 · Cited by 32
Balibegloo, M., Nejadghaderi, S. A., Sadeghalvad, M., Soleymanitabar, A., Nezamabadi, S. S., Saghazadeh, A., & Rezaei, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107796 · Cited by 30
Liu, F., Hardiman, T., Wu, K., Quist, J., Gazińska, P., Ng, T., Purushotham, A. D., Salgado, R., Guo, X., Pinder, S. E., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00292-y · Cited by 26
Oshi, M., Kawaguchi, T., Yan, L., Peng, X., Qi, Q., Tian, W., Schulze, A. K., McDonald, K.-A., Narayanan, S., Young, J. S., et al. (2021) · PubMed · Cited by 33
Du, X., Gao, L., Liu, J., Zhang, C., Liu, Q., Wang, H., & Chen, T. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02387-z · Cited by 34
Breast cancer immune microenvironment: from pre-clinical models to clinical therapies
Wilson, B. E., Gorrini, C., & Cescon, D. W. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06431-0 · Cited by 31
Clinical Trials of Oncolytic Viruses in Breast Cancer
Carter, M. E., Koch, A., Lauer, U. M., & Hartkopf, A. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803050 · Cited by 29
Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?
Gupta, R. K., Roy, A. M., Gupta, A. K., Takabe, K., Dhakal, A., Opyrchal, M., Kaliński, P., & Gandhi, S. (2022) · Cancers · doi:10.3390/cancers14081856 · Cited by 34
“Therefore, the standard systemic treatment option for early-stage TNBC was, until recently, limited to (neo)adjuvant chemotherapy followed by surgery and radiation [2].”
BackgroundResultInfluentialImmunotherapy and breast cancer: an overview
Mezni, E., Béhi, K., & Gonçalvès, A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000878 · Cited by 27
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer
File, D. M., Pascual, T., Deal, A. M., Wheless, A., Perou, C. M., Dees, E. C., & Carey, L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06700-6 · Cited by 35
Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy
Si, X., Ji, G., Ma, S., Chen, H., Shi, Z., Zhang, Y., Tang, Z., Song, W., & Chen, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.028 · Cited by 27
Hattori, M., Masuda, N., Takano, T., Tsugawa, K., Inoue, K., Matsumoto, K., Ishikawa, T., Itoh, M., Yasojima, H., Tanabe, Y., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5757 · Cited by 28
Nanotechnology Applications in Breast Cancer Immunotherapy
Wang, R., Kumar, P., Reda, M. M., Wallstrum, A., Crumrine, N. A., Ngamcherdtrakul, W., & Yantasee, W. (2023) · Small · doi:10.1002/smll.202308639 · Cited by 36
Escalating de-escalation in breast cancer treatment
Sacchini, V., & Norton, L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06685-2 · Cited by 30
Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26
Krishnamurthy, S., Jain, P., Tripathy, D., Bassett, R. L., Randhawa, R. S., Hassan, M., Huang, W., Yang, H., Kummar, S., Wilding, G., et al. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00181 · Cited by 39
Jung, J.-J., Cheun, J.-H., Kim, S., Koh, J., Ryu, J. M., Yoo, T.-K. R., Shin, H.-C., Ahn, S. G., Park, S., Lim, W., et al. (2024) · Journal of Breast Cancer · doi:10.4048/jbc.2023.0265 · Cited by 26
“Therefore, the need for additional treatment for minimal residual lesions, which may be overlooked in our study, is expected to be rare [28].”
BackgroundAn Integrated Care Approach to Improve Well-Being in Breast Cancer Patients
Fabi, A., Rossi, A., Mocini, E., Cardinali, L., Bonavolontá, V., Cenci, C., Magno, S., Barberi, V., Moretti, A., Besharat, Z. M., et al. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01500-1 · Cited by 32
Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment
Yang, Y., Li, H., Yang, W., & Shi, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1441667 · Cited by 34
“Based on these results, the FDA approved atezolizumab plus nab-paclitaxel and pembrolizumab plus chemotherapy for patients with early-stage and metastatic TNBC patients respectively with PD-L1 expression of 1% or more (11).”
BackgroundGriewing, S., Lechner, F., Gremke, N., Lukac, S., Janni, W., Wallwiener, M., Wagner, U., Hirsch, M., & Kuhn, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05964-3 · Cited by 26
“Nevertheless, neither does this approach allow for a conclu - sive comparison of treatment modalities or cancer subtypes (i.e., DCIS versus invasive, Her2 positive versus Her2 negative, Luminal A versus Luminal B, TNBC versus HR + or early-stage versus metastatic carcinoma) nor one should expect the cases to produce,…”
InfluentialInnate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Jiang, X., & Lin, W. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202423280 · Cited by 33
Kim, J., Jung, H. H., Sohn, I., Woo, S., Cho, H., Cho, E. Y., Lee, J. E., Kim, S. W., Nam, S. J., Park, Y. H., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05874-1 · Cited by 27
Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer
Schmidt, M., Edlund, K., Hengstler, J. G., Heimes, A.-S., Almstedt, K., Lebrecht, A., Krajnak, S., Battista, M. J., Brenner, W., Hasenburg, A., et al. (2021) · Cancers · doi:10.3390/cancers13143626 · Cited by 26
Cilibrasi, C., Papanastasopoulos, P., Samuels, M. E., & Giamas, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112015 · Cited by 32
Immunotherapy for Triple-Negative Breast Cancer
Cao, Y., Chen, C., Tao, Y., Lin, W., & Wang, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122003 · Cited by 33
Chen, N., Higashiyama, N., & Hoyos, V. (2021) · Biomedicines · doi:10.3390/biomedicines9121863 · Cited by 28
Dixon-Douglas, J. R., Loibl, S., Denkert, C., Telli, M. L., & Loi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351186 · Cited by 31
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
Li, W., Le, N. N., Onishi, N., Newitt, D. C., Wilmes, L. J., Gibbs, J., Carmona-Bozo, J. C., Liang, J., Partridge, S. C., Price, E. R., et al. (2022) · Cancers · doi:10.3390/cancers14184436 · Cited by 31
Tison, T., Loap, P., Arnaud, E., Cao, K. I., Bringer, S., Kissel, M., Maraadji, S., Mainguené, J., Pierga, J., Lerebours, F., et al. (2023) · Advances in Radiation Oncology · doi:10.1016/j.adro.2023.101384 · Cited by 31
“7 In fact, in this series, the main cause of discontinuation of pembrolizumab was related to suspicion of cardiac adverse events occurring during the neoadjuvant treatment and was related to the injection of pembrolizumab or the chemotherapy.”
BackgroundEdlund, K., Madjar, K., Lebrecht, A., Aktas, B., Pilch, H., Hoffmann, G., Hofmann, M., Kolberg, H.-C., Boehm, D., Battista, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2662 · Cited by 24
Chen, G., Gu, X., Zhang, X., Yu, X., Yu, X., Xue, J., Li, A., Zhao, Y. D., He, G., Tang, M., et al. (2023) · eLife · doi:10.7554/elife.91737 · Cited by 30
Gao, W., Sun, L., Gai, J., Cao, Y., & Zhang, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297260 · Cited by 29
“Chemotherapy remains currently the chief systemic treatment option for TNBC patients [16, 17], under the fact that many TNBC patients miss the surgical window at the time of late diagnosis [18] as well as display resistance to immunotherapy with no appropriate responsive predictor [19].”
BackgroundTolaney, S. M., DeMichele, A. M., Takano, T., Rugo, H. S., Perou, C. M., Lynce, F. C., Parsons, H. A., Santa-Maria, C. A., Rocque, G. B., Yao, W., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2357534 · Cited by 31
“The co-primary end points w er e patholog ic c omplet e response (pCR) and ev ent-fr ee survival (EFS) [ 10 ].”
BackgroundIm, S., Cortés, J., Cescon, D. W., Yusof, M. M., Iwata, H., Masuda, N., Takano, T., Huang, C., Chung, C.-F., Tsugawa, K., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00679-7 · Cited by 37
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy
Feng, D., Pu, D., Ren, J., Liu, M., Zhang, Z., Liu, Z., & Li, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189193 · Cited by 33
Drug delivery for platinum therapeutics
Liu, H., Zou, J., Li, X., Ge, Y., & He, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.006 · Cited by 28
Fu, T., Jin, X., He, M., Chen, Y.-Y., Yang, Y., Chen, L., Zhang, H.-Y.-L., Fan, L., Wu, J., Wang, Z.-H., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adj7808 · Cited by 32
García‐Tejedor, A., Fernández-González, S., Ortega, R., Gil‐Gil, M., Pérez, H., Fernández-Montolí, M.-E., Stradella, A., Recalde, S., Soler, T., Petit, A., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05970-2 · Cited by 27
Immunotherapy in breast cancer: A clinician's perspective
Chaudhuri, S., Thomas, S., & Münster, P. N. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.01.001 · Cited by 26
Anderson, K. S., Erick, T. K., Chen, M., Daley, H., Campbell, M., Colson, Y. L., Mihm, M. C., Zakka, L. R., Hopper, M., Barry, W. T., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06562-y · Cited by 25
“%) had TNBC. Eighty-six percent of patients had a mastectomy, and 86% had a partial response to neoadjuvant therapy.”
BackgroundInfluentialDumas, É., Laot, L., Coussy, F., Grandal, B., Daoud, E., Laas, E., Kassara, A., Majdling, A., Kabirian, R., Jochum, F., et al. (2022) · Cancers · doi:10.3390/cancers14112671 · Cited by 30
“Following the recent FDA approval of pembrolizumab, in combination with chemotherapy in the neoadjuvant setting [1], immunotherapies may be added to the therapeutic arsenal against BC in the near future.”
InfluentialZhao, S., Yan, C., Lv, H., Yang, J., You, C., Li, Z., Ma, D., Xiao, Y., Hu, J., Yang, W., et al. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.06.008 · Cited by 31
Boissière‐Michot, F., Chateau, M., Thézenas, S., Guiu, S., Bobrie, A., & Jacot, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058424 · Cited by 29
“PD-L1 expression cannot be considered a robust biomarker, as demonstrated in the neoadjuvant setting where pembrolizumab benefit was independent of PD-L1 expression (7, 9).”
BackgroundNie, R., Chen, F., Provencio, M., Wang, Y., van den Ende, T., van Laarhoven, H. W. M., Yuan, S., Pless, M., Hayoz, S., Zhou, Z., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.010 · Cited by 25
The Challenges of Treating Patients with Breast Cancer and Obesity
LeVee, A. A., & Mortimer, J. E. (2023) · Cancers · doi:10.3390/cancers15092526 · Cited by 30
Verghese, G. E., Li, M., Liu, F., Lohan, A., Kurian, N. C., Meena, S., Gazińska, P., Shah, A., Oozeer, A., Chan, T., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6088 · Cited by 29
“In the era of immunotherapy as a treatment choice for TNBC [36], the LN can potentially be used as an observation window for the patient’s systemic immune responses of prognostic value [7,8].”
BackgroundBreast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Gullo, R. L., Marcus, E., Huayanay, J., Eskreis‐Winkler, S., Thakur, S. B., Teuwen, J., & Pinker, K. (2023) · Investigative Radiology · doi:10.1097/rli.0000000000001010 · Cited by 33
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Carvalho, F. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244781 · Cited by 34
Forum on immune digital twins: a meeting report
Laubenbacher, R., Adler, F., An, G. C., Castiglione, F., Eubank, S., Fonseca, L. L., Glazier, J. A., Helikar, T., Jett‐Tilton, M., Kirschner, D. E., et al. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00345-5 · Cited by 29
“(This,infact,recentlyplayedoutfor earlytriplenegativebreastcancerwhenpembrolizumabwasapprovedas partofthestandard-of-caretherapy 31 , thereby necessitating building new databases for all population-based approaches for this disease).”
BackgroundTreatment of Early Breast Cancer
Untch, M., Banys‐Paluchowski, M., Brucker, S. Y., Budach, W., Denkert, C., Ditsch, N., Fasching, P. A., Haidinger, R., Heil, J., Jackisch, C., et al. (2023) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2121-2495 · Cited by 26
“A 43-year-old female patient with a gBRCA1 mutation and a stage II TNBC with lymph node involvement still had a residual tumor after neoadjuvant treatment according to the KN522 study (carboplatin/paclitaxel followed by AC, each plus pembrolizumab) [37].”
InfluentialDonati, B., Reggiani, F., Torricelli, F., Santandrea, G., Rossi, T., Bisagni, A., Gasparini, E., Neri, A., Cortesi, L., Ferrari, G., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0076 · Cited by 27
Bischoff, H., Espié, M., & Petit, T. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01251-y · Cited by 28
“[57] Patients continued pembrolizumab or placebo post-surgery for 9 cycles.”
BackgroundInfluentialHeterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review
Tarantino, P., Hortobágyi, G. N., Tolaney, S. M., & Mittendorf, E. A. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3679 · Cited by 31
Dugo, M., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Seitz, R. S., Nielsen, T. J., Thill, M., Antón, A., Russo, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0149 · Cited by 31
Highly multiplexed imaging reveals prognostic immune and stromal spatial biomarkers in breast cancer
Eng, J. R., Bucher, E., Hu, Z., Walker, C. R., Risom, T., Angelo, M., Ericsson, P. I. G., Sanders, M. E., Chakravarthy, A. B., Pietenpol, J. A., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.176749 · Cited by 27
Bear, H. D., Deng, X., Bandyopadhyay, D., Idowu, M. O., Jenkins, T. M., Kmieciak, M., Williams, M., Archer, G., Gwaltney, L., Dillon, P. M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010294 · Cited by 28
“This finding was similar to the KEYNOTE-522 finding 22 —the percentage of patients that developed disease progression in the pembrolizumab-chemotherapy group after a median follow-up of 15.5 months was 11.8%.”
InfluentialAntonini, M., Mattar, A. P. L., Pereira, T. P., Oliveira, L. L., Teixeira, M. D., Amorim, A. G., Ferraro, O., de Oliveira, L. C., Ramos, M. D. N. M., Cavalcante, F. P., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43069 · Cited by 24
Huynh, M.-M., Pambid, M. R., Jayanthan, A., Dorr, A., Los, G., & Dunn, S. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1818067 · Cited by 25
Jia, H., Wang, X., Liu, W., Qin, X., Hu, B., Ma, Q., Lv, C., & Lu, J. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114057 · Cited by 24
Davey, M. G., Ryan, É. J., Davey, M. S., Lowery, A., Miller, N., & Kerin, M. J. (2021) · British journal of surgery · doi:10.1093/bjs/znab103 · Cited by 24
Jackisch, C., Cortazar, P., Geyer, C. E., Gianni, L., Gligorov, J., Machackova, Z., Perez, E. A., Schneeweiß, A., Tolaney, S. M., Untch, M., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102229 · Cited by 29
Su, Y., Li, C.-C., Lin, Y., & Hsu, C. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730949 · Cited by 24
Ralser, D. J., Klümper, N., Gevensleben, H., Zarbl, R., Kaiser, C., Landsberg, J., Hölzel, M., Strieth, S., Faridi, A., Abramian, A., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000384 · Cited by 25
Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers
Savas, P. S., Salgado, R., & Loi, S. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06287-4 · Cited by 25
Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer
Riaz, N., Burugu, S., Cheng, A. S., Leung, S. C. Y., Gao, D., & Nielsen, T. O. (2021) · Cancers · doi:10.3390/cancers13225769 · Cited by 29
Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer
López‐Camacho, E., Trilla‐Fuertes, L., Gámez‐Pozo, A., Dapía, I., López‐Vacas, R., Zapater‐Moros, A., Lumbreras-Herrera, M. I., Arias, P., Zamora, P. M., Vara, J. Á. F., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112844 · Cited by 31
Construction of ceRNA Networks Associated With CD8 T Cells in Breast Cancer
Chen, Z., Feng, R., Kahlert, U. D., Chen, Z., Roche, L. A. T.-D., Soliman, A. S., Chen, M., Wilde, R. L. D., & Shi, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.883197 · Cited by 26
“6%) for the group of chemotherapy alone (8).”
BackgroundRizzo, A., Cusmai, A., Massafra, R., Bove, S., Comes, M. C., Fanizzi, A., Rinaldi, L., Acquafredda, S., Gadaleta‐Caldarola, G., Oreste, D., et al. (2022) · Cells · doi:10.3390/cells11121857 · Cited by 25
Huo, Y., Shao, S., Liu, E., Li, J., Tian, Z., Wu, X., Zhang, S., Stover, D. G., Wu, H., Cheng, L., et al. (2022) · Cancers · doi:10.3390/cancers14194878 · Cited by 25
“In large clinical trials, approximately half of patients with TNBC have residual cancer after NACT [3,4], and approximately 40% of those with residual disease will develop distant metastasis [5].”
BackgroundNoske, A., Steiger, K., Ballke, S., Kiechle, M. B., Oettler, D., Roth, W., & Weichert, W. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208637 · Cited by 27
Tailoring Treatment for Patients with Inflammatory Breast Cancer
Newman, A. B., & Lynce, F. C. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01077-0 · Cited by 29
Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1–10%) Breast Cancer
Moldoveanu, D., Hoskin, T. L., Day, C. N., Schulze, A. K., Goetz, M. P., & Boughey, J. C. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13846-0 · Cited by 29
Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity
Moisand, A., Madéry, M., Boyer, T., Domblides, C., Blaye, C., & Larmonier, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015048 · Cited by 28
“As such, TNBC patients, whose tumors are considered to be more immunogenic, are more responsive to an immune checkpoint blockade (ICB), such as immune inhibitory receptor PD1 inhibition [13,14].”
BackgroundPD-1H/VISTA mediates immune evasion in acute myeloid leukemia
Kim, T. K., Han, X. N., Hu, Q., Vandsemb, E. N., Fielder, C. M., Hong, J., Kim, K. W., Mason, E. F., Plowman, R. S., Wang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci164325 · Cited by 28
The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review
Narvaez, D. P., Nadal, J. C., Nervo, A., Costanzo, M. V., Paletta, C., Petracci, F. E., Rivero, S. G., Ostinelli, A., Freile, B., Enrico, D. H., et al. (2024) · Cancers · doi:10.3390/cancers16020396 · Cited by 27
“In the case of breast cancer, immunotherapy has become a standard treatment for both advanced and early stages of the disease, specifically targeting certain patient subgroups, like the triple-negative subtype [1].”
BackgroundLongitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Wang, K., Zerdes, I., Johansson, H. J., Sarhan, D., Sun, Y., Kanellis, D. C., Sifakis, E. G., Mezheyeuski, A., Liu, X., Loman, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47932-y · Cited by 26
Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy
Liu, J., Li, B., Li, L., Ming, X., & Xu, Z. P. (2024) · Small · doi:10.1002/smll.202403024 · Cited by 24
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
Barough, M. S., Seyfoori, A., Askari, E., Mahdavi, M., Sarrami‐Forooshani, R., Sadeghi, B., Kazemi, M. H., Falak, R., Khademhosseini, A., Mojtabavi, N., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202403910 · Cited by 25
Shi, Z., Liu, Y., Fang, X., Liu, X., Meng, J., & Zhang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-67795-z · Cited by 25
“In July 2021, pembrolizumab was approved in early-stage, high-risk TNBC neoadjuvant therapy by US Food and Drug Administration (FDA) based on notable improvement in pCR rate and 3-year EFS compared to NACT alone in TNBC 21,22 .”
BackgroundMolecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
Denkert, C., Schneeweiss, A., Rey, J., Karn, T., Hattesohl, A., Weber, K. E., Rachakonda, S., Braun, M., Huober, J., Jank, P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101825 · Cited by 25
CircPVT1 weakens miR-33a-5p unleashing the c-MYC/GLS1 metabolic axis in breast cancer
Palcau, A. C., Pulito, C., Pascale, V. D., Casadei, L., Valerio, M., Sacconi, A., Canu, V., Rutigliano, D., Donzelli, S., Sardo, F. L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03355-1 · Cited by 24
Li, H., Chang, Y., Jin, T., & Zhang, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03769-z · Cited by 35
Zhang, Q., Wang, M., Li, Y., Zhang, H., Wang, Y., Chen, X., Yao, L., Cui, M., Dong, H., Li, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02254-3 · Cited by 28
Artificial intelligence in breast pathology: Overview and recent updates
Datwani, S., Khan, H., Niazi, M. K. K., Parwani, A. V., & Li, Z. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105819 · Cited by 31
Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors
Sun, L., Arbesman, J., & Piliang, M. P. (2020) · Archives of Dermatological Research · doi:10.1007/s00403-020-02094-x · Cited by 25
Zhao, J., Meisel, J. L., Guo, Y., Nahta, R., Hsieh, K. L., Peng, L., Wei, Z., O'Regan, R. M., & Li, X. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05819-8 · Cited by 23
Kasimir‐Bauer, S., Keup, C., Hoffmann, O., Hauch, S., Kimmig, R., & Bittner, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01658 · Cited by 23
Fujiwara, Y., Horita, N., Namkoong, H., & Galsky, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.012 · Cited by 23
Martelli, V., Latocca, M. M., Ruelle, T., Perachino, M., Arecco, L., Beshiri, K., Razeti, M. G., Tagliamento, M., Cosso, M., Fregatti, P., et al. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s274283 · Cited by 25
Semba, T., Wang, X., Xie, X., Cohen, E. N., Reuben, J. M., Dalby, K. N., Long, J. P., Phi, L. T., Tripathy, D., & Ueno, N. T. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab128 · Cited by 28
Nemeth, A., Chaudet, P., Leporq, B., Heudel, P., Barabas, F., Trédan, O., Treilleux, I., Coulon, A., Pilleul, F., & Beuf, O. (2021) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-021-00941-0 · Cited by 24
The Comprehensive Cancer Center: Development, Integration, and Implementation
Aljurf, M., Majhail, N. S., Koh, M., Kharfan-Dabaja, M. A., & Chao, N. J. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-82052-7 · Cited by 29
Sieluk, J., Song, Y., Freimark, J., Huang, M., Haiderali, A., Berman, R. B., Wang, T., Signorovitch, J., & Hirshfield, K. M. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01913-5 · Cited by 23
Gandhi, S., Brackstone, M., Hong, N. J. L., Grenier, D., Donovan, E. K., Lu, F., Skarpathiotakis, M., Lee, J., Boileau, J.-F., Perera, F. E., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06522-6 · Cited by 28
Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Cejalvo, J. M., Falato, C., Villanueva, L., Tolosa, P., González, X., Pascal, M., Canes, J., Gavilá, J., Manso, L., Pascual, T., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102392 · Cited by 26
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.